News & Updates

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

Treating seizures with intravenous lacosamide appears to be safe and is associated with low rates of adverse events among critically ill children and neonates, as reported in a study.

Platelet-rich fibrin matrix (PRFM) compares favourably with platelet-rich plasma (PRP) in the treatment of chronic trophic ulcer associated with leprosy, as shown in the results of an observer-blind, noninferiority randomized controlled trial.

Treatment with anticoagulants helps improve survival in patients with cirrhosis and portal vein thrombosis independently of recanalization, suggests a study. However, anticoagulation may increase the risk of nonportal hypertension-related bleeding.